When people start subjecting their pets to their toxic relationship patterns, you know it’s cause for concern. After dumping their emotional baggage on them and making them companions, Aussies are now having to let go of their pets in light of the growing economic crisis. During Covid, more and more people adopted pets, perhaps to
Read More
Picture living in an ideal world where everyone wins—you, your clients, and your crops (albeit not your insects). This is the utopia that Bio-Gene Technology (ASX: BGT) aims to achieve with its chemical-free insecticides that insects don’t develop an immunity to. Together with Israeli developer and marketer of crop production solutions STK Bio-Ag Technologies, the
Read More
Jag Sanger may have been unceremoniously removed from leading media house The Market Herald (ASX: TMH), but that has not derailed their pathways towards profitability with the Company confirming it has a new focus now: digital classified ads. In August last year, The Market Herald acquired Australian online marketplace Gumtree, online car retailer Carsguide and
Read More
Since the easing of regulatory red tape and wider societal acceptance of utilising cannabis for its medical properties, the medicinal cannabis industry has become an intense battleground as researchers have raced towards commercial products. In the case of Cann Group (ASX: CAN) though, they might have just triggered a land mine. Undertaking any form of
Read More
During the lockdown, surely there were many things that you would think of doing once the lockdown is over. For some, it’s popping the long-awaited question or going on an in-store luxury retail therapy to ease the post-lockdown stress. As shoppers have now been able to roam with no restriction, nothing (not even the rate
Read More
How many tabs do you shuffle across every day? Probably more than you need to. Covid and hybrid work have given rise to a slew of online tools, all designed to help you improve your work processes. However, the need of the hour is not to diversify the tool suite but to streamline it. That’s
Read More
As Covid fizzled out, the share price of medical device company Atomo Diagnostics (ASX: AT1) did, too, falling from $0.50 per share in 2020 to $0.059 today. However, the Company is not about to breathe its last with this slump. Instead, it is pivoting to a new diagnostic test—one expected to be worth around $3
Read More
Perhaps China decided to make its own version of the drug or perhaps it proved that it could do so and fast. Whatever it may be, something told the specialised healthcare company Medical Developments International Limited (ASX: MVP) that it wasn’t a good idea to continue pursuing the country. And so, it stopped. Medical Developments
Read More
Incannex Healthcare (ASX: IHL) has reported interim data from its Phase 2 clinical trials to treat anxiety through the use of psychedelics. Upon completion of the trials, the Company will seek to progress this new therapy and offer renewed hope for individuals seeking non-pharmacological solutions to treat mental health. Psilocybin-assisted psychotherapy has emerged as the
Read More
Aussies are some of the most enthusiastic adopters of new clinical drugs. In 2019, 95,000 of us participated in nearly 2,000 clinical trials where Australia is home to many of the world’s leading scientists. In keeping with that, clinical stage biotech company Pharmaxis (ASX: PXS) has a thriving drug development pipeline set to report clinical
Read More
